The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents

Oncology Reports

Volumn 10, Issue 3, 2003, Pages 745-751

  Chowbay, Balram ^a   Sharma, Amarnath ^b   Zhou, Qing Yu ^a   Cheung, Yin Bun ^a   Lee, Edmund J D ^c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b PFIZER INC   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

glucuronidase; Charcoal; CPT 11; Pharmacokinetics; SN 38

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CEFTRIAXONE; CHARCOAL; DRUG DERIVATIVE; IRINOTECAN; VALPROIC ACID;

ANIMAL; ANIMAL MODEL; ARTICLE; CHEMICALLY INDUCED DISORDER; DIARRHEA; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CEFTRIAXONE; CHARCOAL; DIARRHEA; INJECTIONS, INTRAVENOUS; MALE; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; VALPROIC ACID;

EID: 0642375736     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kunimoto T, Nitta K, Tanaka T, et al: Antitumour activity of 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumours. Cancer Res 46: 5944-5947, 1987. (Pubitemid 18018734)
2. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki S and Taguchi T: A phase II study of CPT-11, a new derivative of camptothecin,for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16-20, 1992.
3. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: a new derivative of camptothecin for the treatment of leikaemia and lymphoma. J Clin Oncol 8: 1907-1912, 1990. (Pubitemid 20382355)
4. Atsumi R, Suzuki W and Hakusui H: Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21: 1159-1169, 1991.
5. Kaneda N and Yokokura T: Non-linear pharmacokinetics of CPT-11 in rats. Cancer Res 50: 1721-1725, 1990.
6. Cunningham D, Pyrhonen S, lames RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998. (Pubitemid 28510874)
7. Saliba F, Hagipantelli R, Misset JL, et al: Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhoea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16: 2745-2751, 1998. (Pubitemid 28363040)
8. Gandia D, Abigerges D, Armand JP, Chabot GG, Da Costa L and De Forni M: CPT-11 induced cholinergic effects in cancer patients. J Clin Oncol 11: 196-197, 1993. (Pubitemid 23059997)
9. Gupta E, Lesting TM, Mick R, Ramirez J, Vokes EE and Ratain MJ: Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhoea. Cancer Res 54: 3723-3725, 1994. (Pubitemid 24241187)
10. Takasanu K, Hagiwara T, Hirohashi M, Nomura M, Nagai E, Yokoiu T and Kamataki T: Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumour camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56: 3752-3757, 1996. (Pubitemid 26272025)
11. Takasanu K, Hagiwara T, Hirohashi M, Nomura M, Nagai E, Yokoiu T and Kamataki T: Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumour agent irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42: 280-286, 1998. (Pubitemid 28393844)
12. Kehrer DF, Sparreboom A, Verweij J, et al: Modulation of irinotecan-induced diarrhoea by cotreatment with neomycin in cancer patients. Clin Cancer Res 6: 3451-3458, 2000.
13. Gupta E, Wang X, Ramirez J and Ratain MJ: Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 39: 440-444, 1997. (Pubitemid 27078129)
14. Wolfe R and Gould WW: An approximate likelihood-ratio test for ordinal response models. Stata Tech Bull Rep 8: 149-153, 1998.
15. Gould W and Sribney W: Maximum likelihood estimation with stata. Stata Press, College Station, Tx. 9-10, 1999.
16. Gugler R and Von Unruh GE: Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 5: 67-83, 1980. (Pubitemid 11192690)
17. Pollack GM and Brouwer KLR: Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat. J Pharmacokinet Biopharm 19: 189-225, 1991.
18. Brouwer KLR, Hall ES and Pollack GM: Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats. Biochem Pharmacol 45: 735-742, 1993. (Pubitemid 23064581)
19. Ogiso T, Ito Y, Iwaki M and Yamahata T: Disposition and pharmacokinetics of valproic acid in rats. Chem Pharm Bull 34: 2950-2956, 1986. (Pubitemid 16001852)
20. Kaneda N, Kurita A, Hosokawa Y, Yokokura T and Awaju S: Intravenous administration of irinotecan elevates blood β-glucuronidase activity in rats. Cancer Res 57: 5305-5308, 1997. (Pubitemid 27516368)